Short answer:
Yes—when Yervoy’s core patents expire, the door opens for biosimilar competition, and that usually puts downward pressure on the drug’s price. How quickly that happens, and how much the price will fall, depends on a few factors.
---
1. What’s actually protected by the patents?
| Patent type | What it protects | Typical exclusivity period |
|-------------|------------------|----------------------------|
| Composition of matter (the ipilimumab antibody itself) | The exact amino‑acid sequence and structure | 20 years from filing, but often expires before marketing approval |
| Method‑of‑use (specific indications) | Uses for melanoma, combination with nivolumab, etc. | 20 years from filing, but can be renewed in certain cases |
| Manufacturing process | Unique production steps or purification methods | 20 years from filing |
| Orphan‑drug exclusivity | 7‑year protection for rare‑disease uses | Overlaps with patents but is separate |
| Regulatory exclusivities (U.S. FDA) | 5 years of data exclusivity for biologics (or 10 if orphan‑drug status applies) | Begins when the drug is approved |
Because Yervoy is a biologic (a monoclonal antibody), it’s protected by patent law and also by regulatory exclusivities that last beyond the patent life. That means even after patents expire, Yervoy may still be the only drug the FDA has approved for certain indications for several years.
---
2. When do the patents actually expire?
* Key composition‑of‑matter patents for ipilimumab filed in the early 2000s are now 20‑year‑old, so they’re either already expired or will expire by 2024‑2025.
* Method‑of‑use patents (e.g., “ipilimumab in combination with nivolumab for melanoma”) can be longer; some of these will extend into the late 2020s.
* Orphan‑drug exclusivity for the melanoma indication ends in 2025 (the 7‑year window from the original approval date in 2011).
* The regulatory data exclusivity that protects the clinical data (the 5‑year period) ends in 2026—the latest that biosimilar manufacturers can rely on that exclusivity.
So, practically speaking, the first real chance for biosimilar entry is around 2025‑2026, when most of the patents and exclusivities have worn off.
---
3. What does “biosimilar entry” mean for pricing?
| Stage | What happens | Typical price effect |
|-------|--------------|----------------------|
| Patent expiry | Competitors can file biosimilar applications. | No immediate price drop; still only the original product. |
| Regulatory approval | The biosimilar must demonstrate “high similarity” to Yervoy with no clinically meaningful differences. | Once approved, the biosimilar can be marketed, but it takes time—often 1–2 years. |
| Market entry | Biosimilars begin to be offered to physicians, hospitals, and payers. | Prices often start 15–30 % lower than the reference product. |
| Payer contracts | Insurance plans negotiate discounts and preferred‑product status. | Bulk discounts and formulary placement can accelerate price erosion. |
| Competition and innovation | Other biologics (e.g., newer checkpoint inhibitors) compete for the same indications. | Prices can fall further as the therapeutic space becomes crowded. |
In the biologics market, it’s common to see a 10–30 % price drop once a biosimilar starts circulating. The actual discount for Yervoy will depend on:
* How aggressively the original manufacturer negotiates with insurers.
* Whether the biosimilar manufacturer offers a “price‑matching” program.
* Market dynamics (e.g., if other checkpoint inhibitors are also in the same indication).
---
4. What’s the likely timeline for Yervoy’s price to change?
| Milestone | Expected year | Notes |
|-----------|---------------|-------|
| Patents & exclusivities expire | 2024‑2026 | Composition patents (2024), orphan exclusivity (2025), data exclusivity (2026). |
| First biosimilar approval | 2026‑2027 | FDA review can take ~1 year after filing. |
| Biosimilar launches | 2027‑2028 | Payer contracts and marketing take additional months. |
| Noticeable price drop | 2028 onward | As the biosimilar gains market share. |
So, while the patents are already in the process of expiring, the price impact will likely start to materialize a few years from now, once a biosimilar is approved and actually reaches the clinic.
---
5. Bottom line
* Patents expiring = potential for lower prices, but the effect is not immediate.
* Biologics need to go through a regulatory “biosimilarity” process, which can add 1–2 years after patent expiry.
* Other exclusivities (orphan status, data exclusivity) can delay market entry until the mid‑late 2020s.
* Once a biosimilar is on the market, Yervoy’s price is likely to fall by 10–30 % depending on payer negotiations and competition from other checkpoint inhibitors.
If you’re a prescriber, insurer, or patient, keep an eye on FDA biosimilar filings and payer formulary updates. That’s where you’ll see the price changes unfold.